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Rabies is a reemerging disease in China. The high in-
cidence of rabies leads to numerous concerns: a potential 
carrier-dog  phenomenon,  undocumented  transmission  of 
rabies virus from wildlife to dogs, counterfeit vaccines, vac-
cine mismatching, and seroconversion testing in patients 
after their completion of postexposure prophylaxis (PEP). 
These concerns are all scientifically arguable given a mod-
ern understanding of rabies. Rabies reemerges periodically 
in China because of high dog population density and low 
vaccination coverage in dogs. Mass vaccination campaigns 
rather  than  depopulation  of  dogs  should  be  a  long-term 
goal for rabies control. Seroconversion testing after vacci-
nation is not necessary in either humans or animals. Human 
PEP should be initiated on the basis of diagnosis of biting 
animals. Reliable national systemic surveillance of rabies-
related human deaths and of animal rabies prevalence is 
urgently needed. A laboratory diagnosis–based epidemio-
logic surveillance system can provide substantial informa-
tion  about  disease  transmission  and  effective  prevention 
strategies.
T
he record of rabies in Chinese history dates back to 556 
b c  in Master Zuo’s tradition of the Spring and Autumn 
annals. He wrote, “In the eleventh month, people in the cap-
ital of Song were chasing a rabid dog. It entered the house 
of Hua Chen” (1). Sporadic descriptions of overt clinical 
signs of rabies can be found in records of various ancient 
civilizations (2). However, robust scientific investigation 
of the disease began only after 1885, with Louis Pasteur’s 
discovery of postexposure vaccination against rabies. In 
the 1930s, a rabies virus (RABV) 3aG strain was isolated 
in Beijing and was eventually developed into a vaccine for 
human immunization. In the 1950s, another RABV strain 
(CTN) was isolated in Shandong Province and was charac-
terized and attenuated as a vaccine for humans. However, 
to date, no dog RABV isolates in China have been devel-
oped into animal vaccines. Few domestically licensed vac-
cines for animal rabies exist, according to the Regulations 
for Veterinary Biologics in China (www.ivdc.gov.cn). The 
disconnection between human and dog rabies in China re-
flects a lack of awareness of the concept of one medicine, 
or health without regard to species, in approaches to rabies 
control in the public health system.
Although great progress has been made internation-
ally  in  rabies  control  and  prevention,  >55,000  persons 
still die of rabies annually worldwide. In China, at least 
108,412 persons died of rabies from 1950 through 2004 
(3). A rabies epidemic occurs every 10 years in China (4). 
Despite high human mortality rates, only ≈30 rabies virus 
isolates have been recorded and partially characterized by 
sequencing (3,5,6). Therefore, human rabies is mainly re-
ported without confirmatory laboratory diagnosis in most 
of China. Few statistics are available for dog rabies, indi-
cating that a diagnosis and surveillance system for animal 
rabies is not fully functional. Obvious inconsistencies exist 
in published results of human rabies diagnosis (6). China 
is now facing another wave of rabies outbreaks resulting 
from the combined consequences of rapid economic devel-
opment, a profitable domestic pet industry, and continuing 
family planning, resulting in increased numbers of family 
pets. Reemerging rabies in China has led to a carrier-dog 
myth, strict pet population control policies, counterfeit vac-
cines (low antigen, generating <0.5 IU of virus-neutralizing   
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antibodies  after  administration),  vaccine  matching,  se-
roconversion testing with an ELISA after completion of 
postexposure prophylaxis (PEP) in humans, virus–neutral-
izing antibody titration in vaccinated animals because of 
inferior vaccines, and other related issues. We discuss these 
issues and suggest a new approach to prevention and con-
trol of rabies when the disease reemerges in an unprepared 
country like China.
Carrier or Asymptomatic Rabies
Typically, rabies is fatal once clinical signs develop. 
Although persistent infections occur regularly for other vi-
rus infections, they have not been documented unquestion-
ably in rabies, mainly because of the added complexity of 
the disease’s relatively long incubation period. The carrier 
or asymptomatic rabies state was once considered to be im-
portant for public health, despite lack of adequate evidence 
that the phenomenon actually exists. This concern has been 
raised repeatedly from the early 1930s until recently (7). 
Reported carrier hosts have included vampire bats (8,9), 
cats (10), dogs (11–15), and hyenas (7). Because rabid dog 
bites are responsible for ≈99% of all human rabies cases in 
the world (16), the possibility of a carrier state or asymp-
tomatic form of canine rabies deserves serious evaluation. 
Unfortunately, this possibility remains highly speculative. 
Although some investigators have questioned reports of a 
carrier state in dogs (17), an author reported RABV isola-
tion from brains of healthy dogs (6). Carrier dog RABV 
isolates were even characterized at the molecular level in 
1996 (15).
Similarly, reports of healthy-dog carriers were con-
secutively  published  in  China  in  1982  (18),  1999  (19), 
2006 (20), and 2007 (21). Tang found that 5 (1.76%) of 
283 healthy-looking dogs in Guangxi province were posi-
tive for RABV by reverse transcription–PCR (RT-PCR) 
and virus isolation (5). Another study showed that 24 of 42 
RABV isolates were taken from dogs or cats classified as 
clinically normal (3). All animals from these studies were 
from areas experiencing rabies epidemics.
All cumulative convincing data for more than half a 
century from various parts of the world call into question 
either the concept of a rabies carrier state or the quality 
of research indicating such a state. Other persistent virus 
infections  routinely  occur  in  lymphocytes,  monocytes, 
macrophages,  and  dendritic  cells  through  the  viruses’ 
curtailment of the host’s antivirus immune responses. Ex-
perimental RABV replication in murine bone marrow mac-
rophages and in human macrophage–like cell lines suggests 
a mechanism of virus persistence (22). However, wild-type 
RABV is highly neurotropic. If RABV persistent infection 
occurs in neurons, these findings contradict the current un-
derstanding of RABV pathogenesis. Clearly, RABV infec-
tion causes minor morphologic changes in neurons but may 
result in neurophysiologic dysfunction. Also, virus persis-
tence generally is life-long in infected hosts. The longest 
surviving presumed carrier dog lived for only 16 months; 
in this dog, the tonsil was found to be the only organ from 
which the virus was isolated (14). No data are available 
concerning how long such carrier dogs survive. In healthy 
vampire bats, the duration of salivary excretion of RABV 
was reported to be 690 days after infection by an extremely 
high dose of RABV (8). Generally, persistent infections are 
characterized by an excess of viruses or virus antigens; free 
antibodies,  which  circulate  without  binding  to  antigens, 
are difficult to detect. However, experimental carrier dogs 
and vampire bats presented high rates of virus-neutralizing 
antibodies in serum in these reports (8,14). From an evo-
lutionary perspective, a carrier dog with normal behavior 
does not pose an advantage for virus survival because bit-
ing when an animal is controlled by an aggressive brain is 
the only major route for RABV to spread. Animal behavior 
change  is  fundamental  for  RABV  survival/transmission. 
Therefore, if carrier dogs exist, they are inferior to rabid 
dogs for disease transmission.
In a report by Zhang (17), 15 dogs that were diagnosed 
as positive by ELISA were confirmed to be negative by the 
standard direct fluorescent antibody (DFA) method. Expla-
nations for these contradictory findings include misidenti-
fication of infected dogs, detection of RABV early in the 
prodromal course once it has reached the central nervous 
system after infection and incubation, and inadequate diag-
nostics. These phenomena, rather than the existence of car-
rier hosts, may explain historical reports of asymptomatic 
rabies in enzootic areas.
Rabies Diagnosis in China
A well-established surveillance system for infectious 
diseases depends on reliable, laboratory-based diagnostic 
methods. Human and animal rabies cases in China have 
been reported mainly on the basis of clinical presentations 
and retrospective epidemiologic surveys. Animal rabies is 
rarely diagnosed in China. Human rabies diagnosis based 
solely on clinical symptoms is unreliable because human 
rabies can be confused with Guillain-Barré syndrome, po-
liomyelitis, and other types of encephalitis (23). Similarly, 
rabies in animals is difficult to distinguish from canine dis-
temper and other encephalitic conditions. Postmortem ra-
bies diagnosis should be routinely performed on rabid ani-
mals, animals that have bitten victims, and human patients 
who die after an animal bite. Antemortem diagnosis of ra-
bies in humans is challenging because of the disease’s long 
and variable incubation period. Also, distribution of virus 
antigens, virus nucleic acids, and antibodies is unpredict-
able at this stage (24). Consequently, all countries should 
establish standardized national rabies diagnostic protocols 
for postmortem examinations.
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The DFA method, first introduced in the 1950s, is the 
global standard procedure for rabies diagnosis. It is simple, 
economical, and reliable (25). This method is approved 
by the World Health Organization (WHO) and the World 
Organisation for Animal Health (OIE) and has served as 
a cornerstone for rabies diagnosis for the past half cen-
tury (26). All rabies diagnostic laboratories should follow 
a single standard protocol (27). Whether such a standard 
exists in China is unclear, and diagnostic reagents, equip-
ment, and qualified diagnosticians are in short supply. The 
ELISA for RABV antigen detection is carried out in a few 
laboratories, but this method requires performance evalua-
tion using the standard DFA method to assess specificity, 
sensitivity, and reproducibility. An ELISA-based rapid ra-
bies enzyme immunodiagnosis (RREID) method that uses 
monoclonal antibodies against nucleocapsid and glycopro-
tein for rabies diagnosis has been developed at the Wuhan 
Institute of Biological Products (3). One analysis used the 
RREID method to detect potential virus antigens in dog 
saliva; when verified by the DFA method, all 15 samples 
showed false-negative results (17).
Much  inconsistency  exists  when  different  methods 
are used for rabies diagnosis (6). Overall, of 76 positive 
samples examined by the DFA method (6, cited as an in-
direct immunofluorescent antibody method), only 36 were 
confirmed by RT-PCR. In a certified rabies reference labo-
ratory, DFA-positive samples should be positive when con-
firmed by a sensitive RT-PCR method. Therefore, in China, 
either the DFA or the RT-PCR, or perhaps both protocols, 
have questionable validity. The high prevalence of rabies in 
China necessitates establishment of a standardized national 
DFA protocol in provincial Centers for Disease Controls 
and veterinary stations. Other methods should be compared 
against the established DFA standard. A direct rapid im-
munohistochemical test (dRIT) using low-cost light mi-
croscopy has been extensively investigated and shown to 
have excellent agreement with the DFA (28). The dRIT can 
be completed within 1 hour, and this method is a feasible 
alternative at the county level for confirmatory rabies di-
agnosis or enhanced field surveillance. The urgent need to 
establish an improved national standard DFA protocol in 
China should take precedence over current efforts to de-
velop ELISA and RT-PCR methods.
Rabies Vaccines and Seroconversion  
Testing in China
From 1885, when the first human rabies vaccination 
occurred, to 1994, when the RV Street–Alabama-Dufferin 
(SAD) B19 strain was engineered with reverse genetics 
(29), methods for RABV manipulation have changed fun-
damentally from random attenuation to defined modifica-
tions. However, the basic concept for rabies vaccine devel-
opment has not changed for more than a century. Several 
major modern human rabies vaccines include duck embryo 
vaccine, commercialized in 1957; human diploid cell vac-
cine, introduced in 1978; purified chicken embryo cell vac-
cine, developed in 1984; and a purified Vero cell rabies 
vaccine (PVRV), developed in the late 1980s.
Human Rabies Vaccines in China
Before the 1980s, nerve tissue-derived Semple vaccine 
was manufactured using the fixed RABV Beijing strain 
3aG, which was isolated in 1931. After the 1980s, primary 
hamster kidney cells (PHKC) rabies vaccine using the same 
3aG strain was investigated as a substitute for nerve tissue 
vaccines (NTVs) (30). In recent years, purified and concen-
trated Vero cell rabies vaccines using the 3aG and CTN-1 
strains have been developed. The PVRV, using a RABV 
purified Vero (PV) strain imported from the US Centers for 
Disease Control and Prevention, is also being developed to 
meet the increasing demand for human rabies vaccine in 
China. In 2001, WHO issued a resolution for the complete 
replacement of NTVs by 2006 with cell-culture rabies vac-
cines. NTVs were gradually replaced by the PHKC vaccine 
during the 1980s in China.
Animal Rabies Vaccines in China
In  contrast  to  human  rabies  vaccine  development, 
animal rabies vaccine development in China has not pro-
gressed. In the United States alone, 11 different rabies vac-
cines are licensed for dogs, 12 for cats, 1 for ferrets, 3 for 
horses, 4 for cattle, and 5 for sheep (31). However, in Chi-
na, only 1 pentavalent vaccine is licensed, and 1 Flury-low 
egg passage (LEP) vaccine for dogs has been tentatively 
approved. No regional RABV isolates were characterized 
for animal vaccine development. The LEP, Evelyn–Rokit-
nicki-Abelseth (ERA), PV, and challenge virus standard 
(CVS) strains being developed as vaccine candidates origi-
nate from other countries and have an unclear biological 
background. The inferior quality of the domestically manu-
factured dog vaccine in China has been documented (32). 
Consequently, development of animal rabies vaccines us-
ing carefully characterized RABV strains should be priori-
tized as a fundamental task.
Some believe that vaccine production should reflect 
the design of matched field isolates for regional control. 
However, vaccine-matching investigations to address con-
cerns about mismatch between vaccine strains and epidemic 
RABV isolates are redundant (21). All fixed RABV strains 
recommended by WHO, such as PV, CVS, LEP, high egg 
passage, ERA, and SAD variants, have been successfully 
used in industrialized countries, where rabies is well con-
trolled. Vaccine quality control and mass production, rather 
than matching, are urgently needed and most important for 
addressing the current rabies problem in China. Any potent 
rabies vaccine will protect against rabies.
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Seroconversion Testing After Vaccination  
or PEP in China
Because human rabies vaccines in China are produced 
in cell culture using modern technology, the vaccine qual-
ity  should  follow  the  standard  recommended  by  WHO. 
The minimum potency for all cell-culture and purified em-
bryonated egg rabies vaccines is 2.5 IU per intramuscular 
dose using the National Institutes of Health test (16). Af-
ter rabies exposure in humans, PEP is initiated or withheld 
based on the postmortem diagnosis of animals that were 
the source of exposure. Modern PEP is a combination of 
active and passive immunization, with 100% efficacy in 
rabies prevention if the process strictly adheres to WHO 
recommended  guidelines  (33,34).  Seroconversion  test-
ing is not needed for patients completing preexposure or 
PEP unless the person is immunosuppressed or protocol 
is not followed (33). However, the seroconversion test is 
routinely performed at the provincial and central levels in 
China, mainly because of fear of rabies. In animal studies, 
virus-neutralizing antibody titer has been shown to be an 
imperfect marker for protection because it varies with time 
and the expertise of technicians performing the assay. For 
titration of rabies antibodies, the fluorescent antibody virus 
neutralization test and the rapid fluorescent focus inhibition 
test are the only methods approved by WHO and OIE (35). 
However,  indirect  ELISA  or  ELISA-based  methods  are 
routinely used and are still being developed in China for se-
roconversion testing after vaccination. Without a standard 
method, efforts to develop novel assays are a poor use of 
limited resources for rabies control in China. Potent rabies 
vaccines do not require routine serologic analysis.
Any failure of vaccination and PEP should be investi-
gated thoroughly and independently to trace potential errors 
in the protocol. A national vaccine adverse-event reporting 
system should be established to track suspected problems 
for safety and efficacy.
Hosts and Virus Phylogeny
In theory, all mammals are susceptible to RABV infec-
tion. In China, dogs play the dominant role in rabies trans-
mission (4,5). Statistically, >95% of human rabies cases in 
China are due to rabid dog bites (16). In isolated serologic 
studies of rabies in wildlife such as badgers, raccoon dogs, 
rodents, and bats, no RABV was successfully isolated from 
these animals. Rodents do not serve as reservoirs for ra-
bies.  In China, all RABV isolates characterized by phy-
logeny using the N and G gene sequences are categorized 
into  classic  RABV  genotype  1  (3,6).  Homology  among 
isolates is >90% at the amino acid level. Although some 
subgroups are suggested, the differences would be minor. 
In addition, RABV isolates from dogs on all continents are 
grouped into genotype 1. Phylogeny analyses reinforce the 
perspective that vaccine matching in China is redundant. In 
a rabies-epidemic region such as China, rabies in wildlife 
may result from spillover from dogs. Without proper inves-
tigation of animal population density and characterization 
of the RABV isolates, wildlife rabies in China can be eluci-
dated only after dog rabies is well controlled.
Interpretation of Rabies in China
The recent reemergence and severe incidence of rabies 
have attracted the attention of scientists and administrative 
authorities  in  China.  However,  efforts  are  distracted  by 
and concerns misleadingly focused on healthy dog carri-
ers, possible rabies in wildlife, vaccine matching, inferior 
or counterfeit vaccines, and seroconversion testing after 
vaccination. In the 1920s, long before the recognition of 
bat and other wildlife rabies and the availability of mod-
ern vaccines, rabies in Japan was successfully controlled 
through mass vaccination of dogs. At present, in large cit-
ies such as Beijing and Shanghai, although animal bites are 
fairly common, rabies cases are rare. In 2006, ≈140,000 an-
imal bites were recorded in Beijing, but few human rabies 
cases were reported (16), mainly because of adequate dog 
vaccination. However, in rural areas of China, dog rabies 
vaccination coverage is <3% (4,32). WHO has determined 
that vaccination coverage >70% is needed to sufficiently 
control canine rabies, but the exact level of sufficient cov-
erage  varies  according  to  demographic,  behavioral,  and 
spatial characteristics of dog populations. Historically, the 
4 rabies epidemic waves in China reflect discontinuous ef-
forts of dog control and vaccination. The periodic recess of 
rabies at 10-year intervals resulted from strict depopulation 
of dogs rather than mass vaccination. The density of 4.5 
dogs/km2 can lead to endemic rabies in vulnerable popula-
tions (36). The current estimated number of dogs in China 
is 80–200 million (5). If dogs are distributed evenly, the av-
erage density of dogs in China is 8–20/km2. The estimated 
population density would be much higher in rabies-endem-
ic provinces. With very low vaccination coverage in dog 
populations, rabies outbreaks are not surprising. The phe-
nomenon of 4 rabies epidemic waves during the last half 
century in China corroborates our interpretation and shows 
that depopulation of dogs alone cannot efficiently control 
rabies. Mass vaccination of dogs has been demonstrated to 
be the most efficient way to control the disease (37,38).
Decisions  to  initiate  or  withhold  PEP  are  based  on 
postmortem diagnosis of the biting animal and use of a 
standardized  method  (27).  Patients  exposed  to  rabies  in 
China were estimated to be between 1% and 10% of the 
population,  according  to  disease  prevalence  in  different 
areas. However, because of China’s weak national animal 
rabies diagnosis network, the number of PEP patients in 
China is probably arbitrary or only roughly estimated. To 
maximize efficiency of the limited resource of human vac-
cines and rabies immunoglobulin for patients at real risk, 
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establishing a systemic rabies diagnosis network is impera-
tive. At a minimum, several million persons are expected to 
require PEP each year.
RABV is highly neurotropic and functionally conser-
vative. It is transmitted mainly through animal bites, al-
though rare nonbite exposure routes have been reported. 
Because of this characteristic, the dissemination of rabies is 
relatively slow. The spread of the disease needs a minimum 
threshold support of host population density (36). There-
fore, the frontline of waves of rabies infections garner little 
public attention. Once the density of dogs reaches a criti-
cal threshold, rabies spreads rapidly, and the spread can be 
accelerated  through  animal  translocation.  However,  the 
animal population itself does not pose a rabies threat. An 
immunized dog population can be a solid barrier to prevent 
rabies from spreading to humans (37,38). The immediate 
challenge for rabies control in China is to stockpile enough 
vaccines for mass dog vaccination campaigns. A reliable 
systemic diagnostic network can support effective epide-
miologic investigation, vaccine campaigns, and initiation 
of PEP by providing multiple opportunities for collabora-
tions that work toward practical, humane, and economical 
rabies elimination in China.
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